Adocia Adocia
  • Adocia
    • About
    • History
    • Management
    • Board of directors
    • Advisory board
  • Products and platforms
    • Pipeline
    • Technology Platforms
  • Careers
    • The « Adocians »
    • HR policy
    • Work environment
    • Join us
  • Partnering
  • Investors
  • Media
  • Contact
    • Contact us
    • Map and accessibility
  • Investors
    • Regulated information
    • Stock information
    • Corporate governance
    • General meeting
  • Media
    • Press releases
    • Media
  • EN
    • FR

The ultra-rapid insulin BioChaperone® Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps, Dr. Grégory Meiffren, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)

Previous article“BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
Next article“BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
Adocia
  • Adocia
  • Products and platforms
  • Careers
  • Partnering
  • Investors
  • Media
  • Contact
Contact us
+33(0)4 72 610 610 contact@adocia.com

Adocia
115 Avenue Lacassagne
69003 Lyon, France

2026 © Adocia

  • Site plan
  • Legal notice
  • Privacy policy and cookies policy
  • Managing cookies
Website by Un Brin de CampagneUn Brin de Campagne